ISPOR’s Top 10 HEOR Trends for 2024-2025

By HEOR Staff Writer

January 12, 2024

Introduction:

The International Society for Health Economics and Outcomes Research (ISPOR) recently released its biennial report detailing the top 10 Health Economics and Outcomes Research (HEOR) trends for 2024-2025. This report, the fifth of its kind, offers a compelling glimpse into the future of healthcare. Providing key trends such as Real-World Evidence (RWE), drug pricing, and Artificial Intelligence (AI) taking centre stage.

The Dominance of Real-World Evidence:

RWE has consistently featured in ISPOR’s reports, therefore appearing as the top trend in the three most recent publications. It is increasingly being used to supplement Randomised Controlled Trials (RCTs) in healthcare decision-making, highlighting its growing significance in the industry.

The Recurring Theme of Drug Pricing:

Drug pricing remains a critical concern, featuring as the second trend in the report. However, the introduction of the Inflation Reduction Act (IRA) in the United States, which allows Medicare to negotiate drug prices, could potentially impact global drug development and innovation.

The Rise of Artificial Intelligence:

AI, the third trend, is becoming an integral part of our daily lives and the healthcare sector. From chatbots to machine learning, AI is being utilised in various ways to provide valuable insights in HEOR.

Balancing Innovation and Affordability:

Furthermore, the fourth trend focuses on fostering innovation while ensuring affordable pricing. This balance is vital for the development of new technologies in the healthcare sector.

In conclusion, the ISPOR HEOR trends report presents a comprehensive overview of the top trends shaping the future of healthcare. As pressures on healthcare systems worldwide continue to increase, these trends provide invaluable insights for stakeholders to inform and improve healthcare decisions.

Reference url

Recent Posts

Novartis Drug Pricing Agreement

By João L. Carapinha

January 7, 2026

Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via Trump...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...
Africa Medicine Roadmap: Paving the Way for Sustainable Access to Quality Pharmaceuticals
The WHO Regional Office for Africa launched a 10-year roadmap (2025-2034) that ensures sustainable access to affordable, safe, and quality medicines while tackling high costs, supply chain issues, and substandard products. The Africa medicine roadmap builds on the African Medicines Agency (AMA), ...